Karyopharm Therapeutics
KPTI
$1.10
Share price
3.77%
Change (1 day)
-71.43%
Change (1 year)
Categories
Karyopharm Therapeutics (KPTI) - Cash on Hand
Cash on Hand as of December 2023 : $0.19 B
According to Karyopharm Therapeutics
's latest financial reports the company has $0.19 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Karyopharm Therapeutics - Cash on Hand chart (from 2012 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.19 B | -31.13% |
| 2022-12-31 | $0.27 B | 21.59% |
| 2021-12-31 | $0.22 B | -8.28% |
| 2020-12-31 | $0.24 B | -4.85% |
| 2019-12-31 | $0.26 B | -20.18% |
| 2018-12-31 | $0.32 B | 124.07% |
| 2017-12-31 | $0.14 B | 13.06% |
| 2016-12-31 | $0.12 B | -26.24% |
| 2015-12-31 | $0.17 B | -14.63% |
| 2014-12-31 | $0.20 B | 31.9% |
| 2013-12-31 | $0.15 B | 39791.05% |
| 2012-12-31 | $0.39 M | -94% |
| 2011-12-31 | $6.51 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | $7.27 B | 3,702.18% | 🇺🇸 USA |
 Merck MRK | $7.09 B | 3,605.02% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $9.67 B | 4,951.11% | 🇺🇸 USA |
 Exelixis EXEL | $0.99 B | 419.89% | 🇺🇸 USA |